To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

The Biomedical Research Community Responds to the Opioids Crisis

As part of a larger national effort to address the opioid crisis, the FNIH is leading the planning effort for a potential public-private scientific partnership that includes the NIH, FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and more than 30 biopharmaceutical companies.

Partnership for Accelerating Cancer Therapies (PACT)

https://fnih.org/sites/default/files/final/pdf/APPENDIX%20D_PACT%20Guidelines_v2_01142019_0.pdfThe Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $220 million launched by the National Institutes of Health, the FNIH and 12 leading pharmaceutical companies as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the FNIH.

International Summit in Human Genetics and Genomics

The International Summit in Human Genetics and Genomics is a five-year initiative (2016-2020) designed to help developing nations build and expand their knowledge base, infrastructure, systems and technologies in genetics and genomics. Each fall, researchers from abroad travel to the National Institutes of Health in Bethesda, Maryland for one month of in-person training at the National Human Genome Research Institute (NHGRI). The Summit helps them to understand the prevalence and basis of genetic diseases in their nations and to address these public health challenges. The 2020 Summit will be held on August 31 - October 1, 2020.

Cancer Research Fund

The Cancer Research Fund enables individuals to support cancer research at the National Cancer Institute (NCI).

Sallie Rosen Kaplan Fund for Women Scientists in Cancer Research

The Sallie Rosen Kaplan Postdoctoral Fellowship for Women Scientists in Cancer Research is a highly competitive, unpaid, annual, one-year program that provides additional mentoring opportunities, networking, seminars and workshops to female National Cancer Institute postdoctoral fellows to help them to transition to independent research careers.

The Pew Scholars and Fellows Program in the Biomedical Sciences

The Pew Scholars and Fellows Program in the Biomedical Sciences provides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The Pew Biomedical Scholars Program makes grants to selected academic institutions to support the independent research of outstanding individuals and the Pew Latin American Fellows Program provides support for young scientists from Latin America to receive postdoctoral training in the United States.

Accelerating Medicines Partnership (AMP)

The goal of the Accelerating Medicines Partnership (AMP) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment.

Adam J. Berry Memorial Fund

The Adam J. Berry Memorial Fund assists early career Australian scientists with travel between Australia and the United States to work at the NIH.

Amgen-NIH Scholars Program

In 2015, the NIH became one of 17 leading institutions taking part in the Amgen Scholars Program, a training program that enables undergraduates to participate in cutting-edge research opportunities at world-class institutions.

Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED)

The study was implemented using shared and harmonized protocols across the eight sites to gather an enormous amount of data (physical, cognitive assessments, diet, illness and enteric infection, socio-economic status, etc.) to enable identification and characterization of factors associated with negative impacts on a child’s growth, development and vaccine response early in life.